INFLARX NV's ticker is IFRX and the CUSIP is N44821101. A total of 27 filers reported holding INFLARX NV in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $422,123 | +592.0% | 141,652 | +326.3% | 0.01% | +900.0% |
| Q1 2022 | $61,000 | -61.4% | 33,229 | 0.0% | 0.00% | -75.0% |
| Q4 2021 | $158,000 | -3.7% | 33,229 | -47.5% | 0.00% | -20.0% |
| Q3 2021 | $164,000 | -34.9% | 63,341 | -25.4% | 0.01% | -37.5% |
| Q2 2021 | $252,000 | -27.6% | 84,900 | -4.7% | 0.01% | -38.5% |
| Q1 2021 | $348,000 | +176.2% | 89,123 | +256.9% | 0.01% | +160.0% |
| Q4 2020 | $126,000 | +18.9% | 24,969 | 0.0% | 0.01% | -16.7% |
| Q3 2020 | $106,000 | -9.4% | 24,969 | -1.9% | 0.01% | -25.0% |
| Q2 2020 | $117,000 | -29.9% | 25,444 | -41.9% | 0.01% | -42.9% |
| Q1 2020 | $167,000 | -29.8% | 43,783 | -27.1% | 0.01% | -33.3% |
| Q4 2019 | $238,000 | -37.7% | 60,056 | -61.1% | 0.02% | -40.0% |
| Q3 2019 | $382,000 | +70.5% | 154,507 | +117.5% | 0.04% | +75.0% |
| Q2 2019 | $224,000 | – | 71,032 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,766,038 | $56,955,000 | 17.85% |
| RA Capital Management | 1,967,148 | $63,441,000 | 4.12% |
| Cormorant Asset Management, LP | 1,487,265 | $47,964,000 | 3.55% |
| Redmile Group, LLC | 2,027,700 | $65,393,000 | 2.22% |
| EMORY UNIVERSITY | 77,554 | $2,501,000 | 1.66% |
| Eventide Asset Management | 275,000 | $8,869,000 | 0.37% |
| Birchview Capital, LP | 16,000 | $516,000 | 0.35% |
| Artal Group S.A. | 500,000 | $16,125,000 | 0.34% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,385,659 | $76,938,000 | 0.18% |
| Baker Brothers Advisors | 258,824 | $8,347,000 | 0.06% |